Clinical trial · Interventional
Safety and Efficacy of Intrathecally Administered Magnesium Sulfate
Safety and Efficacy of Intrathecally Administered Magnesium Sulfate Added to Morphine and Local Anesthetics for Major Abdominal Cancer Surgery
NCT03459417CI-TRIAL-00042259completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Magnesium sulfate safety profile has been documented by histopathological analysis in experimental studies. magnesium sulfate added to local anesthetics decrease postoperative opioid requirements.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Cancer | Malignant Abdominal Neoplasm | ALIAS | 0.90 |
| Abdominal Pain | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intrathecal morphine+LA | Procedure | — | UNRESOLVED |
| intrathecal morphine+LA+ Mg sulp. 100 | Procedure | — | UNRESOLVED |
| intrathecal morphine+LA+ Mg sulp. 50 | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- intrathecal morphine+LA
- description
- patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine.
- interventionNames
- Procedure: intrathecal morphine+LA
- type
- ACTIVE_COMPARATOR
- label
- intrathecal morphine+LA+Mg sulp. 50
- description
- patients will receive intrathecal 15 mg (3 mL) of LA (hyperbaric bupivacaine 0.5%) intrathecal with 0.5 mg preservative free morphine + magnesium sulfate 50 mg.
- interventionNames
- Procedure: intrathecal morphine+LA+ Mg sulp. 50
- type
- ACTIVE_COMPARATOR
- label
- intrathecal morphine+LA+ Mg sulp.100
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * patients with ASA physical status II or III, 21-year-old or older with major abdominal cancer surgery Exclusion Criteria: * significant coexisting, hepatorenal, or other end organ disease, obesity (BMI \> 38 kg/m2), contraindication to regional anesthesia and sensitivity to local anesthetic drugs
References
Publications (0)
Data not yet available
No reference posted for this study.